Literature DB >> 8418158

Protective activity of anti-exotoxin A monoclonal antibody against mice infected with toxin-producing Pseudomonas aeruginosa.

T Kohzuki1, Y Eguchi, M Kato, K Irie, H Ohtsuka, A Higuchi, H Noguchi.   

Abstract

The neutralizing and protective effect of murine monoclonal antibody (MAb) 3C7 (IgG1) against Pseudomonas aeruginosa exotoxin A was examined in an experimental mouse model of infection with exotoxin A-producing strains. Treatment with MAb 3C7 blocked the reduction of functional elongation factor 2 (EF-2) in the liver of mice but could not clear the bacteria. Administration of gentamicin caused bacteria to be cleared but did not block reduction of hepatic EF-2 level. Treatment with either MAb 3C7 or gentamicin individually did not prolong time to death; however, the combined therapy with both MAb 3C7 and gentamicin cleared bacteria and blocked the reduction of hepatic EF-2 level, resulting in a significant increase in the survival rate of mice. These results suggest that anti-exotoxin A MAbs show effectiveness against pseudomonal infection caused by exotoxin A-producing strains.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8418158     DOI: 10.1093/infdis/167.1.113

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   7.759


  3 in total

1.  Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon.

Authors:  V C Dreisbach; S Cowley; K L Elkins
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  Comparative immunochemistry of two fragments from domains Ib and III of Pseudomonas aeruginosa exotoxin A.

Authors:  K Rutault; M J Vacheron; M Guinand; G Michel
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.609

3.  Protection against exotoxin A (ETA) and Pseudomonas aeruginosa infection in mice with ETA-specific antipeptide antibodies.

Authors:  H S El-Zaim; A K Chopra; J W Peterson; M L Vasil; J P Heggers
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.609

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.